Abstract
The nonstructural protein 3 (NSP3) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains a conserved macrodomain enzyme (Mac1) that is critical for pathogenesis and lethality. While small molecule inhibitors of Mac1 have great therapeutic potential, few have been described. Here, we report the structure-based development of several chemical scaffolds exhibiting low- to sub-micromolar affinity for Mac1 through iterations of computer-aided design, structural characterization by ultra-high resolution X-ray protein crystallography, and binding evaluation with in-solution assays. Potent scaffolds were designed with in silico linkage of previously obtained fragment hits and ultra-large library docking screens of more than 450 million molecules. In total, 160 hits comprising 119 different scaffolds were discovered and 152 Mac1-ligand complex crystal structures were determined, typically to 1 Ã… resolution or better. The structure-activity-relationships emerging from this study may template future drug development against Mac1. Summary Computational fragment-linking and ultra-large library docking identifies potent inhibitors of the SARS-CoV-2 macrodomain.
Cite
CITATION STYLE
Gahbauer, S., Correy, G. J., Schuller, M., Ferla, M. P., Doruk, Y. U., Rachman, M., … Fraser, J. S. (2022). Structure-based inhibitor optimization for the Nsp3 Macrodomain of SARS-CoV-2. BioRxiv : The Preprint Server for Biology. https://doi.org/10.1101/2022.06.27.497816
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.